Physician profile
Swati Arora
NPI 1639304082
$190,112.63
in general payments reported to CMS, 2019-2025
19 companies · $68K in 2025
The $68K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2021: $9,476 · 2022: $22K · 2023: $51K · 2024: $40K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Honoraria: $48K · Consulting Fee: $29K · Travel and Lodging: $18K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,100 · Food and Beverage: $4,703 · Education: $47.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,605.00 |
| Honoraria | $47,750.00 |
| Consulting Fee | $29,183.00 |
| Travel and Lodging | $18,174.24 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,100.00 |
| Food and Beverage | $4,702.82 |
| Education | $47.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $65,908.36 | 2023-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $35,912.73 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $35,041.84 | 2021-2025 | Benlysta |
| Travere Therapeutics, INC. | $28,906.42 | 2023-2025 | Filspari |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $9,652.83 | 2025 | |
| Novartis Pharmaceuticals Corporation | $8,792.70 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,789.37 | 2024-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $1,320.00 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $239.34 | 2019-2025 | |
| Amgen INC. | $170.86 | 2023-2025 | Tavneos |
| Vifor Pharma, INC. | $113.57 | 2023-2025 | Veltassa |
| Apellis Pharmaceuticals, INC. | $96.60 | 2025 | Empaveli |
| Astrazeneca Pharmaceuticals Lp | $64.02 | 2024-2025 | Farxiga |
| Ardelyx, INC. | $25.39 | 2024 | Ibsrela |
| Scpharmaceuticals INC. | $21.35 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $20.41 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.80 | 2022 | |
| Kite Pharma, INC. | $18.04 | 2023 | Yescarta |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swati Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.